Quantitative phosphoproteomics has in recent years revolutionized understanding of cell signaling, but it remains a challenge to scale the technology for high-throughput analyses. Here we present a rapid and reproducible phosphoproteomics approach to systematically analyze hundreds of samples by fast liquid chromatography tandem mass spectrometry using data independent acquisition (DIA). To overcome the inherent issue of positional phosphopeptide isomers in DIA-based phosphoproteomics, we developed and employed an accurate site localization scoring algorithm, which is incorporated into the Spectronaut software tool. Using a library of synthetic phosphopeptides spiked-in to a yeast phosphoproteome in different ratios we show that it is on par with the top site localization score for data-dependent acquisition (DDA) based phosphoproteomics. Single-shot DIA-based phosphoproteomics achieved an order of magnitude broader dynamic range, higher reproducibility of identification and improved sensitivity and accuracy of quantification compared to state-of-the-art DDA-based phosphoproteomics. Importantly, direct DIA without the need of spectral libraries performed almost on par with analyses using specific project-specific libraries. Moreover, we implemented and benchmarked an algorithm for globally determining phosphorylation site stoichiometry in DIA. Finally, we demonstrate the scalability of the DIA approach by systematically analyzing the effects of thirty different kinase inhibitors in context of epidermal growth factor (EGF) signaling showing that a large proportion of EGF-dependent phospho-regulation is mediated by a specific set of protein kinases.
INTRODUCTION (Brief and focused)
Site-specific protein phosphorylation is one of the most important post-translational modifications (PTMs) as it can rapidly modulate a protein's function by changing its activity, subcellular localization, interactions or stability 1 . It is a highly dynamic modification that regulates essentially all cellular signaling networks. Deregulated phospho-signaling is therefore a hallmark of cancer and many other diseases. Major advances in phosphopeptide enrichment strategies, instrument performance and computational analysis tools have made mass spectrometry-based phosphoproteomics the method of choice for the study of protein phosphorylation on a global scale. Large-scale quantitative phosphoproteomics has proven to be successful in addressing unsolved questions in cell signaling and biomedicine [2] [3] [4] [5] . However, the majority of successful phosphoproteomics studies typically involves days or even weeks of measurements by liquid chromatography tandem mass spectrometry (LC-MS/MS) to analyze few cellular conditions with sufficient depth to identify and pinpoint the functional phosphorylation sites. Moreover, current tandem mass spectrometric sequencing speed and the semi-stochastic nature of data-dependent acquisition (DDA) make it challenging for phosphoproteomics to systematically and reproducibly analyze phosphorylation sites across large numbers of samples. This limits its application for high-throughput applications such as drug screening.
With the advent of fast scanning high-resolution tandem mass spectrometers, DIA has appeared as powerful alternative to DDA in shotgun proteomics [6] [7] [8] . In a DIA analysis, all (phospho)peptides within a predefined mass-to-charge (m/z) window are co-fragmented and the resulting fragments measured together. This analysis is repeated as the mass spectrometer goes through the full mass range, which facilitates systematic measurement of all peptide ions regardless of their intensity and overcomes the precursor selection problem of DDA. DIA typically provides broader dynamic range, higher peptide identification rates, improved reproducibility of identification, and accuracy for quantification. However, due to the multiplexed fragment ion spectra, DIA requires more elaborate data processing algorithms and software solutions for spectral deconvolution, which typically make use of pre-recorded spectral libraries.
Moreover, apart from the unambiguous identification of the phosphopeptide sequence, the deconvoluted tandem mass spectra should contain sufficient information to localize phosphorylation sites with single amino acid resolution 1 .
To address these issues, we have developed an optimized label-free quantitative phosphoproteomics approach combining fast liquid chromatography tandem mass spectrometry with site-specific data-independent acquisition (DIA). This approach allowed us to systematically and reproducibly analyze more than ten thousand phosphorylation sites across hundreds of samples. We developed and employed algorithms to accurately localize phosphorylation sites in DIA datasets and determine their fractional stoichiometry on a system-wide scale. We apply this strategy to identify phosphorylation site targets of ten major protein kinases in the epidermal growth factor signaling pathway 9 .
RESULTS (General description of the method followed by its validation)
Comparison of DDA and DIA for large-scale quantitative phosphopeptide analysis
To enable large-scale phosphoproteomics studies with increased depth and throughput, it is necessary to reduce the amount of input protein, improve workflow reproducibility and decrease mass spectrometry instrument time usage. With this in mind we optimized a fast and scalable single-shot analysis workflow based on high-throughput magnetic Ti-IMAC bead enrichment of phosphopeptides from 200 ug of starting tryptic peptide material ( Figure 1A ). With this approach we routinely quantify ~7000 phosphopeptides in just 15 min of LC-MS/MS analysis time with fast 28 Hz Higher-energy Collisional Dissociation (HCD) 10 scanning method on a Q Exactive HF-X mass spectrometer 8 with overall MS/MS identification rates of more than 50%. This is close to 500 unique phosphopeptides per minute of gradient time, which is significantly more identifications than the commonly-used TiO2-based workflow 8 .
However, even with the very fast and improved methodology, we seemed to have reached the limit for data-dependent acquisition (DDA) for phosphoproteomics with current instrumentation.
Conversely, data-independent acquisition (DIA) can in principle overcome this limitation of sequential DDA by analyzing peptide ions in parallel. This is achieved by co-isolating co-eluting peptide ions in predefined mass windows, fragmenting them together and analyzing all the resulting fragment ions simultaneously. However, few attempts have been reported on applying DIA to large-scale (phospho)proteomics [11] [12] [13] [14] [15] . To address this problem we developed a PTM-specific workflow for peptide-centric DIA that combines the recovery rate of library-based extraction with high confidence site localization algorithm rivaling the current gold standard based on DDA.
Initially, we optimized the instrument settings for best DIA performance. Due to the co-fragmentation of multiple precursors with different charge-states in DIA, it is not possible to employ the charge-state dependent collision energy (CE) scaling of DDA. To identify the optimal collision energy settings for DIA, we recorded spectral libraries at four different normalized CE values and analyzed corresponding DIA runs with CE values fixed at charge-state of two.
Analyzing the DIA files with the different spectral libraries revealed that the best compromise for maximizing identification of differently charged precursors was to record spectral libraries with NCE of 28 and analyze subsequent DIA runs with NCE of 25 at charge state 2 ( Supplementary Figure 1A ). Next, we optimized the overlap between adjacent mass windows in DIA for best quantification by quantifying precursors in overlapping regions in a DIA setup in which we systematically shifted the mass windows. From this analysis, we found that setting a fixed overlap of 1 Da between adjacent mass windows assured optimal quantification of precursors with m/z values at the edges of isolation windows ( Supplementary Figure 1B ) . We also tested different DIA acquisition methods to find the optimal one for fast phosphoproteomics by changing scan cycle times using different mass window widths, number of windows and HCD resolution settings ( Supplementary Figure 1C ). All acquisition methods identified comparable numbers of phosphopeptides, which in DIA is defined as unique phosphorylated elution group precursors. However, the best quantitative performance judged by coefficient of variation (CV) between replica was achieved by the fastest scanning method employing 2 second cycle time with 48 mass windows of 14 Da widths using 15,000 resolution HCD fragmentation with maximum injection time of 22 ms ( Supplementary Figure 1D ).
Using this optimized DIA method with 15 min LC gradients, we identified almost three times as many elution group precursors and twice as many phosphopeptides compared to the number of DDA peptide-spectrum matches (PSMs) and phosphopeptides, respectively ( Figure 1B, see methods section ). In addition, the DIA raw files were also searched with directDIA (dDIA). In this approach, spectral libraries are generated directly by searching deconvoluted pseudo-MS/MS spectra from DIA data against a peptide database. For this process, Pulsar, the search engine in Spectronaut, applies the same search settings as DDA searches in MaxQuant.
This library-independent dDIA strategy also worked well with twofold increase in precursors matched and 75% increase in phosphopeptides ( Figure 1B ). DIA further showed a significantly higher overlap of phosphopeptide identifications between replica compared to DDA ( Figure 1C and 1D ). Importantly, the quantitative reproducibility was better in DIA with correlation coefficient, R 2 of 0.93 compared to R 2 of 0.89 for DDA, even though DIA covered an additional order of magnitude of absolute precursor intensities ( Figure 1E and Figure 1F ). This is likely due to the fact that DIA makes more efficient use of the ion beam by sampling more ions in MS/MS mode compared to DDA throughout the entire LC-MS analysis ( Figure 1G ). Quantifying the difference reveals an approximate 6-fold higher fragment ion count measured in DIA compared to DDA mode ( Figure 1H ). We next assessed the quantification accuracy and precision of the DIA and DDA approaches in a regulated phosphopeptide sub-population spiked into a complex sample background. For this purpose, we made use of a mixed species approach in which we diluted phosphopeptides enriched from yeast at different ratios into a fixed background of HeLa phosphopeptides and analyzed them by DDA, dDIA and DIA ( Figure 1I ). This strategy allows to assess how the acquisition methods quantify the expected ratios of the yeast phosphopeptides of 0.25:1, 0.5:1, 1.5:1 and 2:1. As expected, dDIA and DIA were both able to quantify up to twice as many phosphopeptides as DDA ( Supplementary Figure 1E ). Based on box-plot analysis, all three methods very accurately estimated the expected ratios on median across all comparisons ( Figure 1J ). However, the interquartile ranges were significantly smaller for DIA compared to DDA and generally dropped at the higher loads (2:1) compared to the more dilute sample (0.25:1). This indicates that phosphopeptides of higher intensity are better quantified as expected. Conversely, the human phosphopeptides did not show regulation between the conditions ( Supplementary Figure 1F ).
To better assess quantification precision, we next calculated the mean squared error (MSE) as the sum of positive bias and variance for each method, which represent the quantification error in accuracy and precision, respectively ( Figure 1K ). Based on this, DIA yields the highest precision and highest accuracy at all ratios analyzed. DDA showed lower precision compared to dDIA at high intensity ratios (2:1), but better precision at low intensity ratios (0.25:1). To test if the accurate and precise quantification of DIA translated into a better identification of significant regulation, we used the significance d-score of the SAM test 16 to calculate true-positive-rates (TPR) and false-positive-rates (FPR) of the regulated phosphopeptides for the DDA and DIA approaches ( Figure 1L ). Plotting them against each other created a receiver operating characteristic (ROC) curve, in which best performing methods should achieve a TPR of 1 before increasing their FPR over 0. Focusing on the left part of the ROC curve plot, where the FPR is lowest, we see that DIA and dDIA shows the steepest TPR increase at all tested ratios compared to DDA.
DIA-specific phosphorylation site localization algorithm
To compensate for the wider isolation windows applied in DIA, we developed a PTM localization algorithm for peptide centric analysis utilizing information not available in standard DDA data.
This includes full isotopic patterns for fragment ions and the possibility of generating short elution chromatograms to correlate with the targeted precursor peak shape. The latter allows for systematic removal of any interfering fragment ions that one could not account for in DDA.
These two aspects are combined with additional scores based on fragment ion intensities and mass accuracy into a specific weighted score for each fragment, which is then used to calculate a specific site localization score ( Supplementary note 1 ).
Briefly, during the standard DIA analysis, the algorithm starts out by detecting and classifying all potential peak groups for a peptide precursor in the library. From the DDA files, we on average correctly localized 93.6 phosphorylation sites from singly phosphorylated peptides with 1.4% error rate on wrongly assigned sites ( Figure 2D ). We required at least 0.75 localization probability (Class I sites) as in previous analyses 2 , which in this case equates to an estimated FDR of 1.5%. Applying the same score cutoff of 0.75 for the DIA dataset results in correct identification and localization of 136.2 phosphorylation sites on average with 1.7% error rate of incorrectly assigned sites, indicating that site localization FDR at this cutoff value is comparable to that of DDA analyzed with MaxQuant but achieving higher site coverage in DIA. The site localization FDR when analyzing multiply phosphorylated peptides were somewhat higher but comparable between DDA and DIA with error rates of 12.4% and 10.8% respectively but the underlying statistics were limited due to fewer candidates. Notably, in opposition to DDA for which the number of synthetic phosphopeptide sites identified is significantly hampered at low dilutions, DIA maintained a relatively high identification rate across all dilutions, indicating that DIA outperformed DDA in sensitivity and dynamic range ( Figure 2E ).
We also analyzed the DIA dataset of the synthetic phosphopeptides using dDIA without a spectral library and found that in this case we needed to apply a higher score probability cutoff of 0.99 to achieve error rates comparable to library-based DIA and DDA ( Supplementary   Figure 2 ). However even with this stringent cutoff, dDIA on average correctly identified and localized 128.8 phosphorylation sites, which was one-third more than DDA.
Technical comparison of DDA and DIA in a biologically relevant setting
We next evaluated if the increased coverage of localized phosphopeptides in DIA over DDA translates into an advantage in a cell signaling study. For this purpose, we used EGF-stimulated retinal pigment epithelium (RPE1) cells treated with different MEK kinase inhibitors as a model system ( Figure 3A ). Briefly, cells were pretreated for 30 minutes with 0.5uM or 5uM of Cobimetinib, or 0.5uM or 5uM of PD-032591 prior to 10 minutes EGF stimulation, 10 minutes EGF only or untreated cells as a control. All conditions were prepared as biological triplicates, phosphopeptides from 200 ug of whole cell tryptic digests were enriched by Ti-IMAC and analyzed with 15 minute gradients by DDA and DIA.
For DIA, we tested the effect of using different spectral libraries and dDIA. We recorded a project-specific spectral library consisting of ~40,000 phosphorylation sites by deep phosphoproteome profiling 19 . We fractionated the same EGF-stimulated cells using massive offline high-pH reversed phase chromatography based fractionation combined with DDA analysis of individual fractions measured on the same 15 minute online LC-MS gradient as for the DIA analyses, which should be an ideal reference dataset ( Supplementary Figure 3A and Supplementary Figure 3B ). As an alternative to this, we created an even larger community-based spectral library of ~50,000 phosphorylation sites by combining two previous large-scale HeLa (phospho)proteome studies 20, 21 ( Supplementary Figure 3C With comparable data formats for both DDA and DIA, we first looked at the numbers of identified phosphopeptides and localized phosphorylation sites for each of the different methods, with more than ten thousand sites identified in all ( Figure 3B ). As expected, DDA with 20,056 phosphopeptides covering 12,454 sites identified less sites than DIA with project-specific spectral library with 29,186 phosphopeptides covering 13,934 sites. Conversely, the larger community-based library only identified 19,913 phosphopeptides and 11,385 sites, which is comparable to DDA. However, combining the two spectral libraries provides the best coverage with 30,912 phosphopeptides and 14,835 sites. Interestingly, dDIA yields similar number of phosphopeptides and sites as DDA and DIA with the community library.
To assess the biological effect of the different kinase inhibitor treatments on cellular phospho-signaling, we performed an analysis of variance (ANOVA) statistical test to identify significantly regulated sites. For this test, we only used phosphorylation site ratios quantified in all three biological replicates of at least one condition. Due to its lower precision and phosphopeptide coverage, DDA yielded 532 significantly regulated phosphorylation sites, whereas all DIA methods identified nearly twice the number of regulated sites ( Figure 3B ).
Next, we wanted to assess if and to what degree the regulated sites identified by DDA and DIA provided biological insights into EGF-dependent phospho-signaling in context of MEK inhibition as expected. To do this, we performed unsupervised hierarchical clustering of the DIA significant sites ( Figure 3C ) and the DDA significant sites ( Figure 3D ), which revealed an overall similar pattern of regulation between the different conditions. The pattern was the same for the other DIA methods ( Supplementary Figure 3D ). Linear sequence motif analysis of the EGF-upregulated phosphorylation sites that were largely unaffected by the kinase inhibitor treatment revealed that both DDA and DIA could correctly identify the EGF-dependent but MEK-independent AKT kinase substrate motif RxRxx[s/t]. Reassuringly, the ERK1/2 kinase substrate motif Px[s/t]P was significantly enriched among the MEK-dependent sites as expected ( Figure 3E ). This analysis demonstrated that DIA and DDA identified the same biology on localized phosphosite-level -AKT and ERK activation as the major signaling axes downstream of EGF -recapitulating known EGF receptor signaling as expected.
Global analysis of fractional phosphorylation site stoichiometry from DIA data
Besides relative quantification of phosphorylation sites, it is valuable to determine their occupancy or absolute stoichiometry. A high fractional stoichiometry combined with dynamic regulation is a strong indication that the site is functional in the cellular context studied 1 . It is possible to determine the absolute occupancy or fractional stoichiometry of phosphorylation sites on a large scale by using ratios observed in both the phosphopeptide, its non-phosphorylated counterpart peptide and the respective protein between treatment conditions from SILAC data 22 and TMT-multiplexed data 23, 24 .
Based on our previous findings 24 , we reasoned that the high quantitative accuracy and the completeness of the DIA phosphoproteomics dataset should allow the extraction of stoichiometry from multiple conditions at the same time. We adapted a recently developed 3D multiple regression model (3DMM)-based approach based on TMT data to label-free DIA. The 3DMM approach integrates information of several experimental conditions and replicates into one stoichiometry model, which uses phosphopeptide-, non-phosphorylated peptide-and corresponding protein-intensities from any multiplexed quantification method. However even for DIA, data quantification of individual sites are not complete when analyzing many experimental conditions. To overcome this issue and retain as much quantitative information as possible, we combined peptide information based on the assumption of linear behavior between equally (non-)regulated peptides, which allowed us to extrapolate peptide intensities to fill in missing values. We implemented both the linear modeling approach and stoichiometry calculation into our Perseus plugin, which thus allows users without prior scripting experience to calculate PTM occupancies from LFQ data ( Supplementary Note 1 ).
To benchmark the performance of the label-free 3DMM stoichiometry approach, we prepared a mixed species sample with fixed phosphopeptide stoichiometries ( Figure 4A ). A phosphopeptide-enriched tryptic yeast digest was split in two equal parts and one half was de phosphorylated using alkaline phosphatase. Mixing together phosphorylated and non-phosphorylated yeast peptides in fixed ratios into a HeLa phosphopeptide background yielded conditions of 1%, 10%, 50%, 90% and 99% phosphorylation site stoichiometry. Each sample was analyzed by DDA and DIA using 15 min LC-MS/MS. Boxplot analysis of the calculated stoichiometry values revealed that both DDA and DIA estimated the expected ratios closely on median across all comparisons. However, the interquartile ranges were significantly smaller for DIA compared to DDA especially at high stoichiometry values, indicating that higher intensity phosphopeptides are better quantified by DIA as expected ( Figure 4B ). To compare the quantification error in terms of accuracy and precision for the 3DMM data, we compared the mean squared errors (MSE) presenting the sum of positive bias and variance for the two methods, respectively, as described above. Based on this, DIA yields the highest precision and highest accuracy at all stoichiometry levels analyzed with the general trend that precision is lowest for highest values, whereas accuracy is more comparable across conditions ( Figure 4C ).
Importantly, DIA was able to generate more than twice as many occupancy values ( Supplementary Figure 4A ), presumably due to its better quantification and higher phosphopeptide coverage ( Supplementary Figure 4B ).
Our data indicates that DIA based stoichiometry estimation is possible with reasonable accuracy and we therefore applied it to the EGF-stimulated and kinase-inhibitor treated RPE1 cell Figure 4B ).
Large-scale DIA phosphoproteomics of hundreds of cell perturbations using a kinase inhibitor panel
To demonstrate the power and scalability of the rapid DIA-based site-specific phosphoproteomics workflow developed here, we applied it to identify phosphorylation site targets of the ten major protein kinases in the epidermal growth factor signaling pathway using a panel of thirty kinase inhibitors ( Figure 5A ). Briefly, EGF-stimulated RPE1 cells were pretreated with an inhibitor in two different concentrations (0.1uM and 1uM) in biological triplicates and each of the 186 samples was analyzed by 15 min LC-MS/MS using DIA. We quantified ~20,000 phosphopeptides across the 62 conditions in triplicates and performed ANOVA significance analysis on the log-transformed normalized intensities, which identified 1275 phosphorylation sites that were regulated in at least one condition. We visualized the regulated sites as a inhibition down-regulates sites that conform to the known GSK3 motif, and mTOR inhibition down-regulated sites with the known mTOR substrate motif as well as substrate sites of its main downstream kinase p70S6K. To further validate the specificity of the kinase inhibitors we analyzed known substrates of the individual kinases and found good reproducibility in our dataset ( Figure 5D ).
DISCUSSION (Brief and focused)
Here we optimized a streamlined phosphoproteomics workflow based on data-independent acquisition (DIA) and developed a PTM localization site algorithm as part of the DIA computational pipeline, which we benchmarked against state-of-the-art DDA-based phosphoproteomics. By analyzing a library of synthetic phosphopeptides, controlled mixed-species phosphoproteomes with technical replication and EGF-stimulated cells in combination with kinase inhibitors with biological replication, we show the robustness, specificity, and high quality of the DIA-based phosphoproteomes. Quantitatively we demonstrate that we can achieve significant greater depth than any previous DIA-based phosphoproteome reported. Moreover, to our knowledge, we present the first systematic analysis of kinase inhibitor characterization by phosphoproteomics using label-free quantification.
More generally, the methodological approach we have developed represents a strategy to quantitatively profile hundreds of phopshoproteomes in a few days from low amount of starting material. While it has been shown previously that sensitive phosphoproteomics starting from 200 ug or less 26 is feasible, this study represents an important advancement in that we use sensitive phosphoproteomics to analyze cellular signaling networks much faster and with greater depth. Furthermore, we demonstrate that stoichiometry calculation using LFQ is principally feasible, which has the potential to help in identifying functionally relevant phosphorylation sites in the future.
There are still limitations to the optimal DIA-based phosphoproteomics workflow. We achieve the best coverage and quantification when using tailor-made project specific spectral library for the DIA analyses, but this requires some effort and may not always be possible. However, predicting peptide retention time and MS/MS spectra 27, 28 might circumvent the necessity of recording spectral libraries for DIA in future. Unfortunately, the current prediction tools are not yet developed for phosphoproteomics.
Alternatively, library-free approaches such as dDIA look very promising for the future. Even though it takes a significant hit in the number of identified phosphopeptides, it is much easier to implement. Importantly, dDIA also may overcome issues with standard DIA, where rare or low abundant phosphorylation sites may get diluted out during library generation. Moreover, we believe that there is still room for improvements in the mass spectrometric technology. Although we show that DIA analyzes about 6-fold more ions in MS/MS mode than DDA, we estimate that by using 48 DIA-windows we are still maximally sampling a few percent of the ion beam at best.
Mass spectrometers with higher duty cycles such as the timsTOF pro 29 
Phosphopeptide enrichment
200ug of peptides were enriched for phosphopeptides using Ti-IMAC magnetic beads (Resyn Biosciences). Enrichments were carried out in protein LoBind 96-well plates (Eppendorf). The plates were mixed using 1300 rpm (Heidolph Titramax 1000, #544-12200-00) and separated in the 96-well plate using a magnetic stand (Thermo Scientific, # AM10027). Ti-IMAC beads were equilibrated twice in 200 µl 70% Ethanol followed by once in 100 µl 1% Ammonia and three times in loading buffer (80% acetonitrile, 1M glycolic acid, 5% TFA). 200 µg peptide mixture was mixed with equal amount of loading buffer and 500 µg Ti-IMAC beads (25 µl) were added and the solution was mixed for 20min. The beads were separated on a magnetic stand for 20s and the supernatant was removed using gel-loader tip connected to vacuum. 200 µl of loading buffer was added and beads were mixed for 2min followed by two washes with wash buffer 1 (80% acetonitrile, 1% TFA) and once with wash buffer 2 (10% acetonitrile, 0.2% TFA).
Phosphopeptides were eluted in three rounds with 80 µl 1% Ammonia for 20 min. Transfer the supernatant to a clean plate and acidify with TFA. Speedvac solution and desalt using C18
StageTips and store at 4°C until MS analysis.
Preparation of spectral libraries
RPE1 cells were stimulated with 125 ng/mL EGF (Chromotek) for 3 and 10 min followed by lysis and digestion as described before. Ultimate 3000 ultra-high performance liguid chromatography Each fraction was dried in a speedvac and reconstituted in phopsho loading buffer and phosphopeptides were enriched as described above. Each fraction was analyzed individually with LC-MS/MS settings as described below.
Stoichiometry
Phosphopeptides enriched from yeast and HeLa cells as described above were each split 50:50. One half was dephosphorylated using rAPid alkaline phosphatase (Sigma-Aldrich; 1ul per 2mg protein starting material) at 37°C 750rpm shaking overnight, while the other half was mock treated using water. Both samples were incubated for 10min at 85°C to inactivate the phosphatase, and then purified on C18 StageTips 30 dynamic exclusion 30sec. DIA data was searched using a spectral library generated from the DDA files, searched with MaxQuant and generated by Spectronaut as described below.
Nanoflow LC-MS/MS
The peptides concentrated in a speedvac and volume were adjusted to 7 μl in loading buffer (5% ACN and 0.1% TFA) prior to autosampling. An in-house packed 15 cm, 75 μm ID capillary column with 1.9 μm Reprosil-Pur C18 beads (Dr. Maisch, Ammerbuch, Germany) was used. An EASY-nLC 1200 system (Thermo Fisher Scientific, San Jose, CA) was and the column temperature was maintained at 40 °C using an integrated column oven (PRSO-V1, Sonation, Biberach, Germany) interfaced online with the mass spectrometer. Formic acid (FA) 0.1% was used to buffer the pH in the two running buffers used. The total gradient time was 19 min and went from 8 to 24% acetonitrile (ACN) in 12.5 min, followed by 2.5 min to 36%. This was followed by a washout by a 1/2 min increase to 64% ACN, which was kept for 3.5 min. Flow rate was kept at 350 nL/min. Re-equilibration was done in parallel with sample pickup and prior to loading with a minimum requirement of 1 μL of 0.1% FA buffer at a pressure of 800 bar.
Spray voltage was set to 2 kV, funnel RF level at 40, and heated capillary at 275 °C. For DDA experiments full MS resolutions were set to 60,000 at m/z 200 and full MS AGC target was 3E6 with an IT of 25 ms. Mass range was set to 350−1400. AGC target value for fragment spectra was set at 1E5 with a resolution of 15,000 and injection times of 22ms and Top12. Intensity threshold was kept at 2E5. Isolation width was set at 1.3 m/z and a fixed first mass of 100 m/z was used. Normalized collision energy was set at 28%. For DIA experiments full MS resolutions were set to 120,000 at m/z 200 and full MS AGC target was 3E6 with an IT of 45 ms. Mass range was set to 350−1400. AGC target value for fragment spectra was set at 3E6. 48 windows of 14 Da were used with an overlap of 1 Da. Resolution was set to 15,000 and IT to 22 ms.Normalized collision energy was set at 25%. All data were acquired in profile mode using positive polarity and peptide match was set to off, and isotope exclusion was on. Peptide Max" set to 25 instead of 6. The yeast phosphopeptide library was generated from yeast phosphopeptides fractionated into 12 and 46 fractions. We used an Ultimate 3000 HPLC system (Dionex) with a Waters Acquity CSH C18 1.7 µm 1x150 mm column on operating at a flow rate of 30 µl/min with two buffer lines as previously described 21 .
Raw data processing
DIA files were processed using Spectronaut with default settings, with "PTM localization" activated and probability cutoff set to 0 (for peptide-level analysis of dilution benchmark) or 0.75, "Data filtering" set to "Qvalue" and "Normalization Strategy" set to "Local Normalization". Unless 
Bioinformatics analysis
Most of the data analysis was performed using custom scripts in R (64bit version 3.6.0) with packages data. table (1.12 
Code availability
Custom R code for the data analysis and the Perseus plugin "Peptide Collapse" are available upon request. 
